Celgene 2007 Fact Sheet

PROFILE

Celgene Corporation, as a leader in global biotechnology, has built an integrated discovery, development and commercialization platform for drug and cell-based therapies that enables the company to continue to develop value within its therapeutic franchise areas of cancer and inflammatory diseases. This target-to-therapeutic platform integrates both small molecule and cell-based and spans the critical functions required to generate a large and diverse pipeline of innovative next generation drugs and cell therapies that address the source of the disease and not just the symptoms.

BUILDING ON SUCCESS

Celgene is delivering the promise of science to patients and their families facing extraordinary challenges with cancer and inflammatory disease through innovative next generation therapies. Driving commercial success and profitability are marketed products, which include REVLIMID®, THALOMID®, ALKERAN®, FOCALIN™ and FOCALIN XR™, cellular and tissue therapeutics, as well as the Ritalin® family of drugs.

REVENUE, R&D, & EPS



NEWS EVENTS SUMMER

Celgene reported record 2nd quarter revenue and operating profits

Celgene announced total revenue was a record $347.9 million for the quarter ended June 30, 2007, an increase of 76.4% over the same period in 2006. The increase in total revenue was driven by REVLIMID® net sales of $181.0 million. This is a 187.2% increase over the same period in 2006. THALOMID® net sales reached $117.7 million compared to $107.2 in the same period last year. ALKERAN® net sales for the second quarter were $18.7 million in 2007 compared to $4.5 million in 2006. Revenue from Focalin™ and the Ritalin® family of drugs totaled $24.8 million for the second quarter of 2007 compared to $17.7 million over the same period last year.

REVLIMID driving expansion

- In September, REVLIMID was approved by the Swiss Agency for Therapeutic Products for previously treated multiple myeloma patients. This is the first regulatory approval for Celgene in Switzerland and REVLIMID is the first oral therapy in Switzerland for multiple myeloma patients in more than forty years.
- The European Commission granted marketing authorization for REVLIMID for previously treated multiple myeloma patients in June. This marked the first approval for REVLIMID outside of the United States and the first Celgene approval in Europe. REVLIMID has been launched in Germany, with France and the UK expected to follow suit during the second half of the year. Celgene now has a presence in more than 30 countries.
- During the month of June alone, there were more than 140 abstracts presented worldwide evaluating the clinical potential of Celgene products, with REVLIMID garnering the most attention.
- At the American Society of Clinical Oncology (ASCO) meeting in June, results of the Eastern Cooperative Oncology Group's study of newly diagnosed multiple myeloma patients were reported. Patients receiving REVLIMID plus low-dose dexamethasone had one year survival of 96.5% compared to 86% of patients treated with the standard dose of dexamethasone and REVLIMID. Researchers reported this was the best survival data ever demonstrated in a phase III newly diagnosed multiple myeloma study.
- During the annual meeting of the European Hematology Association (EHA) in June, doctors reported impressive survival data from a phase II trial that evaluated REVLIMID plus melphalan/prednisone in patients with newly diagnosed myeloma. At two years of follow up overall survival was 91% and 75% of patients remained progression free.
- At the 9th International Symposium on Myelodsyplastic Syndromes in May, updated data revealed REVLIMID can provide long-term survival benefit and prevent progression of the disease in patients with chromosome 5q deletion. In many cases, REVLIMID can help patients with MDS live transfusion-free for several years.
- During the International Myeloma Workshop in June, unprecedented survival data was reported. A pooled update of our two pivotal, large, randomized phase III clinical trials MM009 and MM0010 showed that patients who were previously treated for multiple myeloma who were then given REVLIMID/dexamethasone survived for 35 months.

ORAL ANTI-INFLAMMATORY FRANCHISE

- On May 22, Celgene announced plans to advance the development of leading oral anti-inflammatory candidates across a broad range of inflammatory diseases. CC-10004 (apremilast), an oral TNF antagonist and anti-inflammatory agent has demonstrated significant activity and an excellent side effect profile in a placebo controlled proof-of-mechanism trial in psoriasis. Based on these results, Celgene is accelerating clinical and regulatory strategies for CC-10004 in psoriasis, psoriatic arthritis, rheumatoid arthritis and other inflammatory diseases.

CELGENE CORPORATION

86 Morris Avenue
Summit, NJ 07901
P: 908-673-9000
F: 908-673-9001
www.celgene.com

PRODUCT PIPELINE



IMiDs® Compounds:

- REVLIMID®: Multiple Myeloma (US)
- REVLIMID: MDS deletion 5Q (US)
- REVLIMID: Multiple Myeloma (EMEA)
- REVLIMID: MDS deletion 5Q (EMEA)
- REVLIMID: Multiple Myeloma (SWISS)
- REVLIMID: MDS deletion 5Q (SWISS)
- REVLIMID: MDS
- REVLIMID: CLL
- REVLIMID: NHL
- REVLIMID: Solid Tumors
- CC-4047: Myelofibrosis
- CC-4047: Multiple Myeloma
- CC-4047: Solid Tumors
- CC-11006: Inflammatory/Immunological
- CC-10015: Inflammatory
- CC-13097: Pain
- CC-15965: Inflammatory

THALOMID®:

- Multiple Myeloma
- ENL

ALKERAN®:

- Multiple Myeloma/ Ovarian Cancer

Ritalin® /FOCALIN™:

- FOCALIN: ADHD
- Ritalin LA®: ADHD
- FOCALIN XR™: ADHD

Anti-Inflammatory:

- CC-10004: Psoriasis
- CC-10004: Psoriatic Arthritis
- CC-11050: Inflammatory

Benzopyranes:

- CC-02217113: Cancer
- CC-8490: Cancer

Kinase Inhibitors:

- JNK 401: Acute Myelogenous Leukemia
- JNK 930: Fibrotic Diseases

Ligase Inhibitors:

- E2 Ligase Inhibitor: Cancer

Stem Cells and Tissue Products:

- Lifebank USA: Private Stem Cell Banking
- HPP: Transplants
- PDA-001: Autoimmune/Cancer
- BIOVANCE and Acelagraft™

The products represented as in development and found in the product pipeline are intended for investors and members of the media to provide general information on Celgene. This information is not represented to be a complete description and is subject to change without notice. Celgene Corporation may from time to time update this information but does not warrant that will take place at any particular time nor assume any obligation to update this information.

INVESTOR CONTACT INFORMATION

David W. Gryska,
Senior Vice President and CFO
Email: dgryska@celgene.com

Brian Gill
Vice President
Global Corporate Communications
Email: bgill@celgene.com

CELGENE EXECUTIVE OFFICERS

Sol J. Barer, Ph.D.
Chief Executive Officer

Robert J. Hugin
President and COO

David W. Gryska,
Senior Vice President and CFO

ANALYST COVERAGE

Alliance Bernstein
Bank of America
Bear Stearns
Citigroup Smith Barney
Cowen
Credit Suisse Securities
Friedman, Billings, Ramsey
Goldman Sachs
Jeffries
JMP Securities
JP Morgan Chase
Lazard Capital Markets
Leerink Swan
Lehman Brothers
Merrill Lynch
Morgan Stanley
Robert W. Baird
Rodman & Renshaw
Thomas Weisel Partners
UBS

INVESTMENT CONSIDERATIONS

- Profitable and accelerating revenue growth supporting development of multiple clinical compounds across several high potential programs
- Lead clinical candidate REVLIMID offers near-term life transforming potential to treat inflammatory disease and to turn incurable cancers into chronic diseases
- Cutting edge research in cellular signaling technology delivering next generation therapies with potential to change standard of care
- Strong, evolving intellectual property estate supporting a broad, deep, unencumbered proprietary pipeline addressing large, international commercial opportunities
- Financial strength with over $2.3 billion in cash and marketable securities positioned to support long-term growth strategy
- Effective senior management team experienced in successful execution of corporate strategies